BreatheSuite Inc., a Canadian connected respiratory health company, today announced that it has received 510(K) clearance from the U.S. Food and Drug Administration (FDA) for its BreatheSuite Metered-Dose Inhaler (MDI) V1 device. Approved for both prescription and over-the-counter use, the BreatheSuite device turns existing MDIs into smart inhalers by automatically and objectively monitoring and providing feedback on inhaler adherence and technique for people with asthma and COPD.
Update for Oct. 8, 2021: Did you miss the live stream of the PFDD meeting on childhood asthma? We are also still collecting stories about experiences living with and managing food allergy. See below for more information below on how to watch the recording and submit your comments . To bring the voice of patients and caregivers impacted by asthma in childhood to the forefront of drug development and research, the Allergy & Asthma Network, American Lung Association, American Partnership...
@Tia74 and @AllergyKid2006 - it looks like these types of devices are not currently covered by insurance. At least one existing device has a program to provide them free for patients who qualify. So, I think it will be a wait and see to know how this one will be priced or if there will be a patient assistance program.
When you block a person, they can no longer invite you to a private message or post to your profile wall. Replies and comments they make will be collapsed/hidden by default. Finally, you'll never receive email notifications about content they create or likes they designate for your content.
Note: if you proceed, you will no longer be following .